Emily
Editor, Senior Moderator
http://www.sciencedirect.com/science/article/pii/S0264410X11002131
Vaccine
Volume 29, Issue 16, 5 April 2011, Pages 2933-2937
doi:10.1016/j.vaccine.2011.02.012
Fever following administration of two inactivated influenza vaccines?A survey of parents of New Zealand infants and children 5 years of age and under
Helen Petousis-Harrisa, Tracey Poolea, Robert Booyb, Nikki Turnera
Immunisation Advisory Centre, Department of General Practice and Primary Health Care, University of Auckland, New Zealand
National Centre for Immunisation Research and Surveillance, University of Sydney, Australia
Received 17 November 2010; revised 20 January 2011; Accepted 4 February 2011. Available online 21 February 2011.
Abstract
Due to a dramatic increase in reported febrile convulsions in Western Australia following a routine pediatric influenza vaccination programme we evaluated parental recall of fever in their child following 2010 trivalent influenza vaccine manufactured by either Sanofi Pasteur (Vaxigrip?) or CSL Biotherapies (Fluvax?) to determine if the rates of febrile events in infants and children 5 years and under following administration of either Vaxigrip? or Fluvax? were significantly different.
[snip]
Conclusions
There is considerable variation in reactogenicity between two 2010 seasonal vaccines in infants and young children. Vaxigrip? is significantly less reactogenic when compared to Fluvax? in this population in which Fluvax? is associated with unacceptably high rates of febrile reactions. There has been insufficient safety evaluation of seasonal influenza vaccine safety in this population.
Vaccine
Volume 29, Issue 16, 5 April 2011, Pages 2933-2937
doi:10.1016/j.vaccine.2011.02.012
Fever following administration of two inactivated influenza vaccines?A survey of parents of New Zealand infants and children 5 years of age and under
Helen Petousis-Harrisa, Tracey Poolea, Robert Booyb, Nikki Turnera
Immunisation Advisory Centre, Department of General Practice and Primary Health Care, University of Auckland, New Zealand
National Centre for Immunisation Research and Surveillance, University of Sydney, Australia
Received 17 November 2010; revised 20 January 2011; Accepted 4 February 2011. Available online 21 February 2011.
Abstract
Due to a dramatic increase in reported febrile convulsions in Western Australia following a routine pediatric influenza vaccination programme we evaluated parental recall of fever in their child following 2010 trivalent influenza vaccine manufactured by either Sanofi Pasteur (Vaxigrip?) or CSL Biotherapies (Fluvax?) to determine if the rates of febrile events in infants and children 5 years and under following administration of either Vaxigrip? or Fluvax? were significantly different.
[snip]
Conclusions
There is considerable variation in reactogenicity between two 2010 seasonal vaccines in infants and young children. Vaxigrip? is significantly less reactogenic when compared to Fluvax? in this population in which Fluvax? is associated with unacceptably high rates of febrile reactions. There has been insufficient safety evaluation of seasonal influenza vaccine safety in this population.